James Liu
Biography
Dr. James Z. Liu, MD, PhD, is a physician-scientist, entrepreneur, and innovator with over three decades of experience in medical research, clinical development, and healthcare innovation. He co-founded DrNaturalHealing, Inc. and Tesla BioHealing, Inc., developing groundbreaking energy-based therapies and regenerative health solutions used globally. Dr. Liu has authored 89 patents, 32 publications, and 9 books, and has held leadership roles at Abbott, Johnson & Johnson, AstraZeneca, and Premier Research. His work spans cancer prevention, chronic disease recovery, and the advancement of non-invasive therapeutic technologies.
Research Interest
Led multiple international clinical research projects to develop those anti-cancer drugs for FDA registration: Led key clinical research projects to clinically develop the drugs and medical devices for supporting the FDA registration
Abstract
Biophoton Co-Therapy in Oncology: Early Evidence for Improved Tolerance, Biomarkers, and Clinical Outcomes:
Background/Objective: Cancer care is limited by toxicity, treatment interruptions, and poor quality of life. Biophoton Quantum Medicine (BQM)-application of coherent, ultra-weak light fields-has been proposed as a non-pharmacologic adjunct to restore cellular coherence and support recovery. We synthesized evidence from recent reports to evaluate signals of benefit, safety, and plausible mechanisms relevant to cancer science, diagnosis, and therapeutics.
Methods: Narrative synthesis of: (i) a four-patient oncology case series integrating biophoton co-therapy with standard treatments; (ii) a longitudinal post-chemotherapy lung-cancer case with serial live-blood microscopy and tumor markers; (iii) a mechanistic review of BQM; (iv) a mini-review on unmet medical needs and biophoton mechanisms; and (v) a case report demonstrating genomic-level change after biophoton exposure (to contextualize potential DNA-repair pathways). Device descriptions in these reports note over-the-counter automatic biophoton generators emitting 500-1000 nm fields.
Results:
In the case series, biophoton co-therapy alleviated pancytopenia, fatigue, pain, and other adverse effects, enabling uninterrupted completion of therapy; three of four patients achieved cancer-free status with improved quality of life.
In the post-chemotherapy lung-cancer case, serial microscopy showed progressive improvements in red-cell morphology and plasma terrain, concordant with symptom gains and a 33.5% reduction in squamous cell carcinoma antigen over 23 days, suggesting remission support.
Mechanistic reviews describe BQM restoring cellular coherence, modulating immune responses, and interacting with mitochondrial/DNA dynamics-offering a systems-level, non-toxic adjunctive strategy.
A mini-review outlines biophotons (200-1200 nm) as coherent, information-rich emissions implicated in cellular communication, with external fields potentially entraining disordered oscillations and supporting DNA transcription/repair.
A non-oncology case report documented a decrease in detected genetic mutations from 64 to 29 after six weeks of biophoton therapy, consistent with activation of endogenous DNA-repair pathways-mechanistically relevant to oncology.
Conclusions: Across early reports, biophoton co-therapy appears safe and may improve treatment tolerance, hematologic/microscopic terrain, tumor biomarkers, and clinical outcomes when integrated with standard oncology care. These hypothesis-generating signals, alongside plausible mitochondrial/immune/DNA mechanisms, support prospective controlled trials to define indications, dosing, and responder phenotypes in cancer patients.
